secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001213900-23-083011
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Q3 net loss $9.9M; cash $74M; TARA-002 trials advance with results expected 1H24
--------------------------------------------------------------------------------

- Q3 2023 net loss of $9.9M ($0.87/shr) vs $7.7M ($0.68/shr) in Q3 2022.
- Cash, cash equivalents & investments of $74.0M as of Sept 30, expected to fund ops into Q2 2025.
- R&D expenses rose to $6.2M from $3.5M, driven by TARA-002 clinical trial activities.
- First patient dosed in Phase 2 ADVANCED-2 (NMIBC) and Phase 2 STARBORN-1 (lymphatic malformations) trials.
- Preliminary results from ADVANCED-1EXP expansion trial in NMIBC on track for 1H24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023083011/0001213900-23-083011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023083011/ea187484-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-083011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer